Published in Child Adolesc Psychiatr Clin N Am on April 01, 2008
A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2009) 2.80
The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry (2011) 1.46
Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2011) 1.00
Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry (2012) 0.97
Evolution of stimulants to treat ADHD: transdermal methylphenidate. Hum Psychopharmacol (2009) 0.88
Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker. J Pharm Sci (2014) 0.87
Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder. Behav Brain Funct (2010) 0.86
Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2009) 0.85
Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2014) 0.82
Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. Pharmacogenomics J (2013) 0.79
Characteristics of successful recruitment in prospective pediatric pharmacogenetic studies. Clin Ther (2011) 0.79
DRD4 and DAT1 in ADHD: Functional neurobiology to pharmacogenetics. Pharmgenomics Pers Med (2010) 0.79
The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents. Am J Med Genet B Neuropsychiatr Genet (2008) 0.78
Drug therapy of attention deficit hyperactivity disorder: current trends. Mens Sana Monogr (2012) 0.78
Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates. PLoS One (2014) 0.78
Variants of Dopamine Beta Hydroxylase Gene Moderate Atomoxetine Response in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol (2015) 0.75
Psychopharmacology of ADHD in pediatrics: current advances and issues. Neuropsychiatr Dis Treat (2009) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry (2006) 10.19
Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry (2006) 9.85
Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry (2005) 7.94
The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2006) 4.58
Multiple dopamine D4 receptor variants in the human population. Nature (1992) 4.08
National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics (2004) 3.25
Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem (1995) 3.08
Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry (1996) 3.05
Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol (2001) 2.86
Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet (1995) 2.54
Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics (2001) 2.48
Pharmacogenetics and adverse drug reactions. Lancet (2000) 2.41
Pharmacogenetics in the laboratory and the clinic. N Engl J Med (2003) 2.12
Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry (1999) 1.88
Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry (2004) 1.80
The metabolic fate of amphetamine in man and other species. Biochem J (1970) 1.80
Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry (2004) 1.79
The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet (2005) 1.70
Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol (1997) 1.66
Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (2007) 1.56
The genetics of attention deficit hyperactivity disorder. Clin Psychol Rev (2006) 1.53
Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed (2006) 1.51
The nature and heritability of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am (2001) 1.50
Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet (2005) 1.47
CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther (2000) 1.42
Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology (2005) 1.34
Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther (1995) 1.21
Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. J Child Adolesc Psychopharmacol (2004) 1.19
Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology (2005) 1.15
The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsychopharmacol (2005) 1.15
High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD. J Child Psychol Psychiatry (2005) 1.14
In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry (2005) 1.14
Association of 4-repeat allele of the dopamine D4 receptor gene exon III polymorphism and response to methylphenidate treatment in Korean ADHD children. Neuropsychopharmacology (2006) 1.13
Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry (2005) 1.09
ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry (2003) 1.09
Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet B Neuropsychiatr Genet (2003) 1.08
Dopamine transporter 3'-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology (2006) 1.07
Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry (2003) 1.06
Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics (2002) 1.06
CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry (2007) 1.05
Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry (2007) 1.04
Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry (2004) 1.03
Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc Psychiatr Clin N Am (2006) 1.02
No support for association between the dopamine transporter (DAT1) gene and ADHD. Am J Med Genet B Neuropsychiatr Genet (2005) 1.01
No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2007) 0.99
Coloboma mouse mutant as an animal model of hyperkinesis and attention deficit hyperactivity disorder. Neurosci Biobehav Rev (2000) 0.99
Association and linkage of allelic variants of the dopamine transporter gene in ADHD. Mol Psychiatry (2007) 0.96
Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet (2001) 0.95
Is the alpha-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder? Am J Med Genet B Neuropsychiatr Genet (2003) 0.93
Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry (2005) 0.91
Childhood hyperactivity and psychostimulants: a review of extended treatment studies. J Child Adolesc Psychopharmacol (1993) 0.91
Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics. Pharmacogenomics (2005) 0.90
Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD. Am J Med Genet B Neuropsychiatr Genet (2006) 0.87
Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl) (2002) 0.84
Psychiatric pharmacogenetics: personalizing psychostimulant therapy in attention-deficit/hyperactivity disorder. Behav Brain Res (2002) 0.78
Principles of haplotype mapping and potential applications to attention-deficit/hyperactivity disorder. Biol Psychiatry (2005) 0.77
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry (2005) 2.94
The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-year follow-up. J Am Acad Child Adolesc Psychiatry (2013) 2.48
Subtypes versus severity differences in attention-deficit/hyperactivity disorder in the Northern Finnish Birth Cohort. J Am Acad Child Adolesc Psychiatry (2007) 1.75
Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr (2005) 1.74
A genomewide scan for loci involved in attention-deficit/hyperactivity disorder. Am J Hum Genet (2002) 1.63
Electroencephalography correlates of spatial working memory deficits in attention-deficit/hyperactivity disorder: vigilance, encoding, and maintenance. J Neurosci (2014) 1.58
Meta-analysis of genome-wide linkage scans of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2008) 1.48
Maternal smoking and hyperactivity in 8-year-old children. J Am Acad Child Adolesc Psychiatry (2003) 1.43
Genetic linkage of attention-deficit/hyperactivity disorder on chromosome 16p13, in a region implicated in autism. Am J Hum Genet (2002) 1.39
A genomewide scan for attention-deficit/hyperactivity disorder in an extended sample: suggestive linkage on 17p11. Am J Hum Genet (2003) 1.36
Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry (2006) 1.34
Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry (2003) 1.29
Clinical presentation of attention-deficit/hyperactivity disorder in preschool children: the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol (2007) 1.24
ADHD symptoms and subtypes: relationship between childhood and adolescent symptoms. J Am Acad Child Adolesc Psychiatry (2007) 1.22
Prevalence and psychiatric comorbidity of attention-deficit/hyperactivity disorder in an adolescent Finnish population. J Am Acad Child Adolesc Psychiatry (2007) 1.22
A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord (2005) 1.18
Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2009) 1.16
Attention deficit hyperactivity disorder: fine mapping supports linkage to 5p13, 6q12, 16p13, and 17p11. Am J Hum Genet (2004) 1.13
Polygenic transmission and complex neuro developmental network for attention deficit hyperactivity disorder: genome-wide association study of both common and rare variants. Am J Med Genet B Neuropsychiatr Genet (2013) 1.11
Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2008) 1.11
High loading of polygenic risk for ADHD in children with comorbid aggression. Am J Psychiatry (2013) 1.10
Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet (2008) 1.08
Cortical activity patterns in ADHD during arousal, activation and sustained attention. Neuropsychologia (2009) 1.05
Relationship of family environment and parental psychiatric diagnosis to impairment in ADHD. J Am Acad Child Adolesc Psychiatry (2006) 1.03
Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol (2007) 1.02
Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol (2004) 1.02
Parent versus teacher ratings of attention-deficit/hyperactivity disorder symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol (2007) 1.01
Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr (2008) 1.01
Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord (2009) 1.00
Atypical brain activation during simple & complex levels of processing in adult ADHD: an fMRI study. J Atten Disord (2007) 0.99
Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs (2010) 0.99
Factor structure of parent- and teacher-rated attention-deficit/hyperactivity disorder symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol (2007) 0.97
Mixed-handedness is linked to mental health problems in children and adolescents. Pediatrics (2010) 0.95
ADHD candidate gene study in a population-based birth cohort: association with DBH and DRD2. J Am Acad Child Adolesc Psychiatry (2007) 0.93
Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol (2013) 0.93
Temperament and character profiles and the dopamine D4 receptor gene in ADHD. Am J Psychiatry (2005) 0.93
Familial clustering and DRD4 effects on electroencephalogram measures in multiplex families with attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2010) 0.92
Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol (2007) 0.90
A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD. Neuropsychopharmacology (2012) 0.89
Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol (2007) 0.89
Executive functioning among Finnish adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2007) 0.89
Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. J Child Adolesc Psychopharmacol (2008) 0.87
Atypical brain laterality in adults with ADHD during dichotic listening for emotional intonation and words. Neuropsychologia (2005) 0.86
Atypical alpha asymmetry in adults with ADHD. Neuropsychologia (2009) 0.84
ADHD familial loading and abnormal EEG alpha asymmetry in children with ADHD. J Psychiatr Res (2009) 0.83
Attention deficit hyperactivity disorder pharmacogenetics: the dopamine transporter and D4 receptor. Pharmacogenomics (2012) 0.82
New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs (2004) 0.81
Atypical EEG beta asymmetry in adults with ADHD. Neuropsychologia (2010) 0.80
Adult attention deficit hyperactivity disorder: moving beyond DSM-IV. Am J Psychiatry (2006) 0.79
Effects of source of DNA on genotyping success rates and allele percentages in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol (2007) 0.79
Characteristics and comorbidity of ADHD sib pairs in the Central Valley of Costa Rica. Compr Psychiatry (2011) 0.78
Sex-specific influence of DRD2 on ADHD-type temperament in a large population-based birth cohort. Psychiatr Genet (2012) 0.78
MethyPatch Noven. Curr Opin Investig Drugs (2002) 0.77
Chronic non-episodic irritability in childhood: current and future challenges. Am J Psychiatry (2014) 0.77
Frontostriatal neuroimaging findings differ in patients with bipolar disorder who have or do not have ADHD comorbidity. J Affect Disord (2012) 0.77
Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.77
Genome-wide association study of intelligence: additive effects of novel brain expressed genes. J Am Acad Child Adolesc Psychiatry (2012) 0.77
ADHD comorbidity can matter when assessing cortical thickness abnormalities in patients with bipolar disorder. Bipolar Disord (2012) 0.76
Pharmacological management of preschool ADHD. J Am Acad Child Adolesc Psychiatry (2006) 0.76
Diagnosing and managing complicated ADHD. Prim Care Companion J Clin Psychiatry (2008) 0.75
[Prevalence of and screening for ADHD in Costa Rica]. Vertex (2012) 0.75
New drugs for treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs (2002) 0.75
Hats off: 2010 Journal awards. J Am Acad Child Adolesc Psychiatry (2010) 0.75
Sex subgroup analysis of treatment response to lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol (2012) 0.75
Diagnosing and managing complicated ADHD. J Clin Psychiatry (2007) 0.75